Guangdong Cerebrovascular Disease Translational Medicine Innovation Platform
The Guangdong Cerebrovascular Disease Translational Medicine Innovation Platform (Cerebrovascular Disease Platform) is the first and only provincial-level cerebrovascular translational medicine research platform in Shenzhen. This platform boasts comprehensive scientific research conditions and software support and has established close cooperative relationships with several renowned research institutions in Shenzhen. Led by Shenzhen Second People's Hospital, participating institutions include the Brain Science Research Center of Southern University of Science and Technology, Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences, Shenzhen Institute of Neuroscience, and Shenzhen Brain Research Institute.
The platform encompasses six sub-specialties, including blood-brain barrier damage, neuroplasticity and repair, application of nanobiomaterials, neuroimaging, language function rehabilitation, and more. The research team enjoys excellent scientific research conditions and has completed the construction of four sub-platforms for cerebrovascular research:
Cerebrovascular Disease Cell Culture Platform
Cerebrovascular Disease Animal Model Production Platform
Cerebrovascular Disease Clinical Translation Platform
Small Animal Neurological Function Assessment Platform
The platform is equipped with various instruments and equipment necessary for cerebrovascular research, including animal models for stroke, small animal vital sign monitoring, stereotaxic instruments for brain, laser Doppler brain blood flow monitoring, and neurological function rating instruments. Additionally, there is an animal house to support animal experiments.
Over the past three years, the platform has published 34 SCI papers, with a cumulative impact factor of 225 points. This includes 18 SCI papers with an impact factor above 5, 7 papers with an impact factor above 10, and 18 papers in JCR Zone 1. The platform has secured four National Natural Science Foundation projects and two postdoctoral funds. It has also received the Second Prize for Scientific and Technological Progress in Guangdong Province, been granted 11 invention patents, published one monograph, and trained four postdoctoral fellows.
The core members of the research team all hold doctoral degrees and have been recognized as high-level talents in Shenzhen and overseas high-level talents under the "Peacock Plan." With years of experience in cerebrovascular disease research, the team has a well-structured personnel hierarchy, including members with clinical medicine backgrounds as well as those with expertise in pharmacy, bioengineering, and nanobiomaterials. This multidisciplinary approach facilitates the conduct of cross-disciplinary research on stroke and actively promotes the transformation of research results. The team is actively collaborating with multiple companies, fostering strong partnerships to integrate industry, academia, medicine, research, and application, with the goal of building a platform dedicated to industrial transformation.
